Martin Gary R, Wallace Laurie E, Sigalet David L
University of Calgary, Gastrointestinal Research Group, Calgary, Alberta, Canada, T2T 5C7.
Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G964-72. doi: 10.1152/ajpgi.00509.2003. Epub 2004 Feb 12.
Glucagon-like peptide-2 (GLP-2) is an intestinal trophic enteroendocrine peptide that is associated with intestinal adaptation following resection. Herein, we investigate the effects of GLP-2 in a total parenteral nutrition (TPN)-supported model of experimental short bowel syndrome. Juvenile Sprague-Dawley rats underwent a 90% small intestinal resection and jugular catheter insertion. Rats were randomized to three groups: enteral diet and intravenous saline infusion, TPN only, or TPN + 10 microg.kg(-1).h(-1) GLP-2. Nutritional maintenance was isocaloric and isonitrogenous. After 7 days, intestinal permeability was assessed by quantifying the urinary recovery of gavaged carbohydrate probes. The following day, animals were euthanized, and intestinal tissue was processed for morphological and crypt cell proliferation (CCP) analysis, apoptosis (caspase-3), and expression of SGLT-1 and GLUT-5 transport proteins. TPN plus GLP-2 treatment resulted in increased bowel and body weight, villus height, intestinal mucosal surface area, CCP, and reduced intestinal permeability compared with the TPN alone animals (P < 0.05). GLP-2 treatment induced increases in serum GLP-2 levels and intestinal SGLT-1 expression (P < 0.01) compared with either TPN or enteral groups. No differences were seen in the villus apoptotic index between resection groups. Enterally fed resected animals had a significant decrease in crypt apoptotic indexes compared with nontreated animals. This study demonstrates that GLP-2 alone, without enteral feeding, stimulates indexes of intestinal adaptation. Secondly, villus hypertrophy associated with adaptation was predominantly due to an increase in CCP and not to changes in apoptotic rates. Further studies are warranted to establish the mechanisms of action and therapeutic potential of GLP-2.
胰高血糖素样肽-2(GLP-2)是一种肠道营养性肠内分泌肽,与切除术后的肠道适应性相关。在此,我们研究了GLP-2在全胃肠外营养(TPN)支持的实验性短肠综合征模型中的作用。幼年Sprague-Dawley大鼠接受了90%的小肠切除术并插入颈静脉导管。大鼠被随机分为三组:肠内饮食和静脉输注生理盐水、仅接受TPN或TPN + 10μg·kg⁻¹·h⁻¹ GLP-2。营养维持为等热量和等氮量。7天后,通过定量灌胃碳水化合物探针的尿回收率来评估肠道通透性。第二天,对动物实施安乐死,并对肠道组织进行形态学和隐窝细胞增殖(CCP)分析、凋亡(半胱天冬酶-3)以及钠-葡萄糖协同转运蛋白1(SGLT-1)和葡萄糖转运蛋白5(GLUT-5)转运蛋白表达的检测。与仅接受TPN的动物相比,TPN加GLP-2治疗导致肠重和体重增加、绒毛高度增加、肠黏膜表面积增加、CCP增加以及肠道通透性降低(P < 0.05)。与TPN组或肠内营养组相比,GLP-2治疗使血清GLP-2水平和肠道SGLT-1表达增加(P < 0.01)。切除组之间的绒毛凋亡指数没有差异。与未治疗的动物相比,接受肠内喂养的切除动物隐窝凋亡指数显著降低。本研究表明,单独使用GLP-2,无需肠内喂养,即可刺激肠道适应性指标。其次,与适应性相关的绒毛肥大主要是由于CCP增加,而非凋亡率的变化。有必要进行进一步研究以确定GLP-2的作用机制和治疗潜力。